Novo Nordisk Updates Progress on 2026 DKK 15 Billion Share Buyback
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Novo Nordisk ( (NVO) ).
On 4 February 2026, Novo Nordisk began a share repurchase programme under EU Safe Harbour Rules as part of a broader plan to buy back up to DKK 15 billion of B shares over 12 months. Under the specific tranche running from 4 February to 4 May 2026, the company is targeting up to DKK 3.8 billion of B-share repurchases.
Between the prior update on 30 March 2026 and 1 April 2026, Novo Nordisk repurchased an additional 805,000 B shares, bringing cumulative purchases since 4 February to 9,967,992 B shares at a total value of DKK 2.59 billion. As of 1 April 2026, the company held 27,357,791 B shares as treasury stock, equal to 0.6% of its share capital, underscoring ongoing capital-return efforts that may support earnings per share and signal management confidence in long-term prospects.
The most recent analyst rating on (NVO) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.
Spark’s Take on NVO Stock
According to Spark, TipRanks’ AI Analyst, NVO is a Neutral.
The score reflects strong underlying financial quality and attractive valuation, partially offset by a very weak technical setup (downtrend across all key moving averages) and a cautious near-term outlook from management, including guidance for declining 2026 sales and operating profit amid pricing and policy headwinds.
To see Spark’s full report on NVO stock, click here.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, with a core focus on treating serious chronic diseases rooted in its heritage in diabetes care. The company pioneers scientific breakthroughs, expands access to medicines, and markets its portfolio in about 170 countries, with B shares listed on Nasdaq Copenhagen and ADRs trading on the New York Stock Exchange.
Average Trading Volume: 23,893,892
Technical Sentiment Signal: Sell
Current Market Cap: $162.4B
For a thorough assessment of NVO stock, go to TipRanks’ Stock Analysis page.
